Ceruletide, a CCK-like peptide, attenuates dopamine release from the rat striatum via a central site of action

Kihara, Tsuyoshi; Ikeda, Masato; Ibii, Nobuhiro; Matsushita, Akira

doi:10.1016/0006-8993(92)91585-3

Cited by 12 publications

(5 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is considerable debate as to whether the effect of systemically administered CCK or ceruletide on central DA neurotransmission is peripheral or central in origin. We have demonstrated previously (Kihara et al, 1992) that the inhibitory effect of systemically administered ceruletide on haloperidol-induced DA release in the striatum is not blocked by vagotomy, that locally applied ceruletide produces inhibition of striatal DA release in the same manner as systemic administration, that locally applied proglumide, a CCK receptor antagonist, reverses the effect of subcutaneously administered ceruletide, and that radioimmunoassay shows a small amount of ceruletide in the striatum at 10 min after systemic administration of 160 pg/kg of ceruletide. These findings led us to conclude that a small amount of ceruletide may enter the brain through the blood-brain barrier when given systemically and act directly on CCK receptors in the striatum to produce an inhibitory effect on striatal DA release.…”

Section: Discussionmentioning

confidence: 75%

Influence of Potassium Concentration in Microdialysis Perfusate on Basal and Stimulated Striatal Dopamine Release: Effect of Ceruletide, a Cholecystokinin‐Related Peptide

Kihara

Ikeda

Miyazaki

et al. 1993

Journal of Neurochemistry

Self Cite

View full text Add to dashboard Cite

The in vivo microdialysis method was used to study the effect of the cholecystokinin-related peptide, ceruletide, on extracellular levels of dopamine (DA) in the striatum following perfusion with various K+ concentrations. Increasing the K+ concentration in the perfusate from 4 to 15 or 17.5 mM did not change basal DA release or release evoked by electrical stimulation of the medial forebrain bundle (MFB). However, when the perfusing solution contained 20 or 30 mM K+, dose-dependent reductions of both basal and MFB-stimulated DA release occurred. Subcutaneous administration of ceruletide at 160 micrograms/kg had no influence on the basal or MFB-stimulated DA release with 4 or 15 mM K+ in the perfusate. However, after perfusion with 17.5 mM K+, ceruletide significantly attenuated the basal and MFB-stimulated DA release. Carbachol (10 microM) locally applied via the dialysis probe also attenuated MFB-stimulated DA release after perfusion with 17.5 mM K+. From these results, we conclude that under appropriate depolarization of striatal DA terminals, ceruletide induces further depolarization and inactivation of nigrostriatal DA terminals. The present data suggest that this effect may be mediated via intrinsic cholinergic neurons in the striatum.

show abstract

Section: Discussionmentioning

confidence: 75%

Influence of Potassium Concentration in Microdialysis Perfusate on Basal and Stimulated Striatal Dopamine Release: Effect of Ceruletide, a Cholecystokinin‐Related Peptide

Kihara

Ikeda

Miyazaki

et al. 1993

Journal of Neurochemistry

Self Cite

View full text Add to dashboard Cite

show abstract

“…DVZ (1 mg/kg, i.p.) has been reported to reverse partially the inhibitory effects of ceruletide on haloperidol-induced DA overflow in the striatum (Kihara et al ., 1992), showing that peripheral administration of this antagonist can have effects on central DA levels . Neither of the doses of DVZ tested in the present study (0.1 and 10 mg/ kg, i .p.)…”

Section: Discussionmentioning

confidence: 99%

The CCK‐B Antagonist CI‐988 Increases Dopamine Levels in Microdialysate from the Rat Nucleus Accumbens via a Tetrodotoxin‐ and Calcium‐Independent Mechanism

Corwin

Jörn

Hardy

et al. 1995

Journal of Neurochemistry

View full text Add to dashboard Cite

CI‐988, a water‐soluble, selective cholecystokinin‐B antagonist, was perfused through a microdialysis probe into the anterior nucleus accumbens, posterior nucleus accumbens, or caudate nucleus of anesthetized rats. High concentrations of CI‐988 produced three‐ to fivefold increases in dopamine overflow, at all three sites, that were temporally correlated with the CI‐988 perfusion and returned to baseline levels upon cessation of CI‐988 perfusion. However, the cholecystokinin‐A antagonist CAM‐1481, and the relatively inactive enantiomer of CI‐988, CAM‐1241, also increased dopamine overflow in the nucleus accumbens. Furthermore, the ability of CI‐988 to increase dopamine overflow persisted in the absence of calcium in the perfusate and was not sensitive to tetrodotoxin treatment. The mechanism by which locally administered CI‐988 increases dopamine overflow appears not to be anatomically specific, not selective for one cholecystokinin receptor subtype, and may be nonvesicular.

show abstract

“…Systemic administration of CCK analogs in rats have been shown to modify behavior (Van Ree et al 1983;Nair et al 1986) and brain function (Kihara et al 1992(Kihara et al , 1993 in a manner consistent with a neuroleptic-like action. For example, systemically administered CCK agonists block amphetamine-induced hyperlocomotion (Crawley et al 1981;Van Ree et al 1983;Vasar et al 1991) and modulate central dopamine turnover (Kihara 1992(Kihara , 1993.…”

mentioning

confidence: 99%

“…For example, systemically administered CCK agonists block amphetamine-induced hyperlocomotion (Crawley et al 1981;Van Ree et al 1983;Vasar et al 1991) and modulate central dopamine turnover (Kihara 1992(Kihara , 1993. Based upon these findings, the effects of systemically administered CCK analogs in schizophrenia patients were examined in a series of clinical trials (reviewed in Nair et al 1986 andAlbus 1988).…”

mentioning

confidence: 99%

Antipsychotic Potential of CCK-Based Treatments: An Assessment Using the Prepulse Inhibition Model of Psychosis

Feifel

Reza

Robeck

1999

Neuropsychopharmacology

View full text Add to dashboard Cite

show abstract

Ceruletide, a CCK-like peptide, attenuates dopamine release from the rat striatum via a central site of action

Cited by 12 publications

References 28 publications

Influence of Potassium Concentration in Microdialysis Perfusate on Basal and Stimulated Striatal Dopamine Release: Effect of Ceruletide, a Cholecystokinin‐Related Peptide

Influence of Potassium Concentration in Microdialysis Perfusate on Basal and Stimulated Striatal Dopamine Release: Effect of Ceruletide, a Cholecystokinin‐Related Peptide

The CCK‐B Antagonist CI‐988 Increases Dopamine Levels in Microdialysate from the Rat Nucleus Accumbens via a Tetrodotoxin‐ and Calcium‐Independent Mechanism

Antipsychotic Potential of CCK-Based Treatments: An Assessment Using the Prepulse Inhibition Model of Psychosis

Contact Info

Product

Resources

About